Dear RDI subscriber
The development and testing of the global models that are currently being used to power HIV-TRePS are described in a paper now published online at the Journal of antimicrobial Chemotherapy.
In all three sets of models are described:
1. Global models that do not require a genotype to make their predictions of HIV treatment response
2. Local models that do not require genotype, trained with data form South Africa only
3. Global models that do require a genotype to make their predictions of HIV treatment response
The main findings were:
1. The global models were highly accurate in their predictions of virological response
2. The global models that do not require a genotype were as accurate for patients from South Africa as the local models trained with only South African data and significantly better than the local models at identifying alternative potentially effective combinations of drugs for patients who failed on the new regimen in the clinic
3. The global models, even those that do not use a genotype, were significantly more accurate than genotyping with rules-based interpretation.
4. The global models that require a genotype to make their predictions were marginally but not statistically significantly more accurate in their predictions of response than the models that do NOT require a genotype
The results provide further evidence that these models, freely available via HIV-TRePS have the potential to improve outcomes through optimised and individualised therapy, particularly in settings where genotyping is not available.
The RDI's press release follows and the paper itself can be found here:
We hope you find the paper interesting and that you will alert your colleagues and contacts, particularly those in resource-limited settings, to the existence and potential utility of HIV-TRePS.
Sign In or Register now at:
The RDI team.
Date published: 24th June 2016